Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration.
暂无分享,去创建一个
M. Carrington | L. Montaner | E. Papasavvas | J. Kostman | K. Mounzer | I. Frank | L. Azzoni | P. Tebas | M. Busch | A. Foulkes | S. Deeks | J. Jacobson | A. Mexas | U. O’Doherty | K. Lynn
[1] E. Ruiz-Mateos,et al. Plasmacytoid Dendritic Cells Reduce HIV Production in Elite Controllers , 2012, Journal of Virology.
[2] J. Fellay,et al. Role of retroviral restriction factors in the interferon-α–mediated suppression of HIV-1 in vivo , 2012, Proceedings of the National Academy of Sciences.
[3] F. Bushman,et al. Engineering HIV-Resistant Human CD4+ T Cells with CXCR4-Specific Zinc-Finger Nucleases , 2011, PLoS pathogens.
[4] J. Singer,et al. A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune , 2011, AIDS.
[5] M. Carrington,et al. HLA/KIR restraint of HIV: surviving the fittest. , 2011, Annual review of immunology.
[6] C. Dinarello,et al. Histone Deacetylase Inhibitors for Purging HIV-1 from the Latent Reservoir , 2011, Molecular medicine.
[7] D. Sullivan,et al. Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression. , 2011, The Journal of general virology.
[8] S. Migueles,et al. Elite Suppressors Harbor Low Levels of Integrated HIV DNA and High Levels of 2-LTR Circular HIV DNA Compared to HIV+ Patients On and Off HAART , 2011, PLoS pathogens.
[9] C. Rouzioux,et al. Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial , 2011, AIDS.
[10] A. McMichael,et al. First-Class Control of HIV-1 , 2010, Science.
[11] Jeffrey N. Martin,et al. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals , 2010, AIDS.
[12] M. Altfeld,et al. Innate immune activation in primary HIV-1 infection. , 2010, The Journal of infectious diseases.
[13] D. Heckerman,et al. Additive Contribution of HLA Class I Alleles in the Immune Control of HIV-1 Infection , 2010, Journal of Virology.
[14] M. Malim,et al. Characterization of the Alpha Interferon-Induced Postentry Block to HIV-1 Infection in Primary Human Macrophages and T Cells , 2010, Journal of Virology.
[15] R. Schooley,et al. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. , 2010, The Journal of infectious diseases.
[16] Kristen K. Dang,et al. Genome-Wide mRNA Expression Correlates of Viral Control in CD4+ T-Cells from HIV-1-Infected Individuals , 2010, PLoS pathogens.
[17] L. Montaner,et al. Inability of Plasmacytoid Dendritic Cells To Directly Lyse HIV-Infected Autologous CD4+ T Cells despite Induction of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand , 2009, Journal of Virology.
[18] D. Ge,et al. HLA-C cell surface expression and control of HIV / AIDS correlate with a variant upstream of HLA-C , 2009 .
[19] N. Mehra,et al. Genetic determinants of HIV-1 infection and progression to AIDS: immune response genes. , 2009, Tissue antigens.
[20] Jacques Fellay,et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.
[21] C. Hallahan,et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. , 2008, Immunity.
[22] Jeffrey N. Martin,et al. Evidence for Persistent Low-Level Viremia in Individuals Who Control Human Immunodeficiency Virus in the Absence of Antiretroviral Therapy , 2008, Journal of Virology.
[23] H. Schuitemaker,et al. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy , 2008, AIDS.
[24] B. Walker,et al. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452) , 2008, AIDS.
[25] A. Boasso,et al. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. , 2008, Clinical immunology.
[26] P. Narciso,et al. Interferon may prevent HIV viral rebound after HAART interruption in HIV patients. , 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[27] L. Montaner,et al. NK Cell Lysis of HIV-1-Infected Autologous CD4 Primary T Cells: Requirement for IFN-Mediated NK Activation by Plasmacytoid Dendritic Cells1 , 2007, The Journal of Immunology.
[28] J. Lawrence,et al. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). , 2006, The Journal of infectious diseases.
[29] J Darbyshire,et al. CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.
[30] D. Katzenstein,et al. A Pilot Study Evaluating Time to CD4 T-cell Count <350 cells/mm3 After Treatment Interruption Following Antiretroviral Therapy ± Interleukin 2: Results of ACTG A5102 , 2006, Journal of acquired immune deficiency syndromes.
[31] J. Clot,et al. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon‐α treatment , 2005, The British journal of dermatology.
[32] Tara L. Kieffer,et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. , 2005, JAMA.
[33] L. Montaner,et al. Randomized, Controlled Trial of Therapy Interruption in Chronic HIV-1 Infection , 2004, PLoS medicine.
[34] J. Kahn,et al. HIV RNA testing in the context of nonoccupational postexposure prophylaxis. , 2004, The Journal of infectious diseases.
[35] J. Clot,et al. Interferon-α restores HIV-induced alteration of natural killer cell perforin expression in vivo , 2003 .
[36] J. Clot,et al. Interferon-alpha restores HIV-induced alteration of natural killer cell perforin expression in vivo. , 2003, AIDS.
[37] L. Mimms,et al. Sensitive detection of genetic variants of HIV-1 and HCV with an HIV-1/HCV assay based on transcription-mediated amplification. , 2002, Journal of virological methods.
[38] F. Gheyas,et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. , 2001, Blood.
[39] R. Lempicki,et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[40] V. Calvez,et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. , 1999, AIDS.
[41] T. Chun,et al. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[42] M A Nowak,et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[43] R. Siliciano,et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.
[44] M. Baseler,et al. ANTI-RETROVIRAL EFFECTS OF INTERFERON-α IN AIDS-ASSOCIATED KAPOSI'S SARCOMA , 1988, The Lancet.
[45] J. Metcalf,et al. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. , 1988, Lancet.
[46] E Wetzler,et al. Letter: Type-iv hyperlipidaemia. , 1975, Lancet.